GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SpectraScience Inc (GREY:SCIE) » Definitions » Financial Strength

SpectraScience (SpectraScience) Financial Strength : 0 (As of Sep. 2017)


View and export this data going back to . Start your Free Trial

What is SpectraScience Financial Strength?

SpectraScience has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

SpectraScience did not have earnings to cover the interest expense. As of today, SpectraScience's Altman Z-Score is 0.00.


Competitive Comparison of SpectraScience's Financial Strength

For the Medical Devices subindustry, SpectraScience's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SpectraScience's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SpectraScience's Financial Strength distribution charts can be found below:

* The bar in red indicates where SpectraScience's Financial Strength falls into.



SpectraScience Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

SpectraScience's Interest Expense for the months ended in Sep. 2017 was $-0.61 Mil. Its Operating Income for the months ended in Sep. 2017 was $-0.40 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $1.41 Mil.

SpectraScience's Interest Coverage for the quarter that ended in Sep. 2017 is

SpectraScience did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

SpectraScience's Debt to Revenue Ratio for the quarter that ended in Sep. 2017 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2017 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(6.506 + 1.41) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

SpectraScience has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SpectraScience  (GREY:SCIE) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

SpectraScience has the Financial Strength Rank of 0.


SpectraScience Financial Strength Related Terms

Thank you for viewing the detailed overview of SpectraScience's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


SpectraScience (SpectraScience) Business Description

Traded in Other Exchanges
N/A
Address
11568-11 Sorrento Valley Road, San Diego, CA, USA, 92121
SpectraScience Inc is a US based company focused on developing the WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The firm has developed a technology platform to determine if the tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT operates by using cool, safe UV laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin treatment during the same procedure. The group sells its product in the United States and Europe, of which majority of the sales revenue is derived from the United States.
Executives
Lowell Giffhorn officer: CFO 10875 KEMAH LANE, SAN DIEGO CA 92131
John Pappajohn director 1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
Euclidsr Partners, L.p. 10 percent owner 45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Euclidsr Associates, L.p. 10 percent owner 45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

SpectraScience (SpectraScience) Headlines

No Headlines